MIFEGEN Trademark

Trademark Overview

On Monday, September 13, 2021, a trademark application was filed for MIFEGEN with the United States Patent and Trademark Office. The USPTO has given the MIFEGEN trademark a serial number of 97024941. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, October 3, 2024. This trademark is owned by Danco Laboratories, LLC. The MIFEGEN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the interruption of pregnancy
mifegen

General Information

Serial Number97024941
Word MarkMIFEGEN
Filing DateMonday, September 13, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, October 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 9, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for the interruption of pregnancy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 20, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDanco Laboratories, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNashville, TN 37215
Party NameDanco Laboratories, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNashville, TN 37215

Trademark Events

Event DateEvent Description
Thursday, September 16, 2021NEW APPLICATION ENTERED
Wednesday, October 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 15, 2022ASSIGNED TO EXAMINER
Friday, July 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 20, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 9, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 9, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 4, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, March 16, 2023SOU TEAS EXTENSION RECEIVED
Thursday, March 16, 2023SOU EXTENSION 1 FILED
Thursday, March 16, 2023SOU EXTENSION 1 GRANTED
Tuesday, September 26, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, September 26, 2023SOU EXTENSION 2 FILED
Tuesday, September 26, 2023SOU EXTENSION 2 GRANTED
Monday, March 11, 2024SOU TEAS EXTENSION RECEIVED
Saturday, March 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 11, 2024SOU EXTENSION 3 GRANTED
Monday, March 11, 2024SOU EXTENSION 3 FILED
Tuesday, March 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 3, 2024SOU TEAS EXTENSION RECEIVED
Thursday, October 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 3, 2024SOU EXTENSION 4 FILED
Thursday, October 3, 2024SOU EXTENSION 4 GRANTED

Related Keywords

mifegen pregnancy interruption pharmaceuticals